Three-in-one drug to tackle stubborn TB

Coghlan, Andy
July 2012
New Scientist;7/28/2012, Vol. 215 Issue 2875, p13
This article reports on the drug PaMZ as a treatment for tuberculosis (TB) highlighting its chemical composition of pyrazinamide mixed with antibiotic moxifloxacin, its effectiveness against resistant strains of Mycobacterium tuberculosis, and its potential for treating TB in HIV-positive people.


Related Articles

  • Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. Ängeby, K. A.; Jureen, P.; Giske, C. G.; Chryssanthou, E.; Sturegård, E.; Nordvall, M.; Johansson, A. G.; Werngren, J.; Kahlmeter, G.; Hoffner, S. E.; Schón, T. // Journal of Antimicrobial Chemotherapy (JAC);May2010, Vol. 65 Issue 5, p946 

    Objectives: To describe wild-type distributions of the MIC of fluoroquinolones for Mycobacterium tuberculosis in relation to current critical concentrations used for drug susceptibility testing and pharmacokinetic/ pharmacodynamic (PK/PD) data. Methods: A 96-stick replicator on Middlebrook 7H10...

  • Caspofungin/rifampicin interaction.  // Reactions Weekly;10/6/2012, Issue 1422, p15 

    The article describes the case of a 65-year-old woman who developed Candida (C.) parapsilosis candidaemia due to failure of treatment with caspofungin for C. lusitaniae while receiving rifampicin for Mycobacterium tuberculosis.

  • New Anti-Tuberculosis Drugs in Clinical Development: An Overview. Guillemont, Jerome; Lieby-Muller, Frederic; Lounis, Nacer; Balemans, Wendy; Koul, Anil; Andries, Koen // Current Bioactive Compounds;Jun2009, Vol. 5 Issue 2, p137 

    Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the world's poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third...

  • Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. Rigouts, L.; Coeck, N.; Gumusboga, M.; de Rijk, W. B.; Aung, K. J. M.; Hossain, M. A.; Fissette, K.; Rieder, H. L.; Meehan, C. J.; de Jong, B. C.; Van Deun, A. // Nicotine & Tobacco Research;Feb2016, Vol. 18 Issue 2, p314 

    Objectives: Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was to determine molecular markers...

  • Researchers identify 39 genes related to TB drug resistance. Shafer, Emily; Volansky, Rob; Zacharyczuk, Colleen // Infectious Disease News;Oct2013, Vol. 26 Issue 10, p40 

    The article discusses a study published in a 2013 issue of the periodical "Nature Genetics" that reported the identification of 39 new genes associated with drug resistance in Mycobacterium tuberculosis.

  • Cutting costs on mono-resistant tuberculosis diagnosis could eventually end up being more expensive. Rouzaud, F.; Robledo, J. // Indian Journal of Medical Microbiology;Oct2010, Vol. 28 Issue 4, p412 

    A letter to the editor is presented in response to the article "Combined drug medium with isoniazid and rifampicin for identification of mutli-drug resistant Mycobacterium tuberculosis," by S. Nalini and colleagues.

  • New, novel treatment of multidrug-resistant Mycobacterium tuberculosis. Boeser, Kimberly D. // Infectious Disease News;Jul2013, Vol. 26 Issue 7, p30 

    The article discusses the use of bedaquiline, a diarylquinoline and antimycobacterial, as a novel treatment of multidrug-resistant Mycobacterium tuberculosis (MDR-TB).

  • Comparision of Performance Characteristics of Automated PCR Systems with Culture for Detection of MTB Complex from Clinical Samples in Central India. Desikan, P.; De, S.; Mishra, P.; Jain, A.; Panwalkar, N.; Verma, M.; Maudar, K. K. // Indian Journal of Medical Microbiology;Jul2009, Vol. 27 Issue 3, p277 

    A letter to the editor is presented about the different performance characteristics of automated COBAS AMPLICOR (CA) system and real time polymerase chain reaction (RT-PCR) for detection of mycobacterium tuberculosis in India.

  • Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. Dookie, Navisha; Sturm, A. Willem; Moodley, Prashini // Infection & Drug Resistance;2014, Vol. 7, p223 

    Objectives: Moxifloxacin (MXF) has been advocated for the treatment of extensively drugresistant (XDR) tuberculosis despite resistance to older-generation fluoroquinolones. We investigated the relationship between the minimum inhibitory concentration (MIC) of MXF and mutations in the gyrA and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics